MyMD Pharma up on positive mid-stage trial data for muscle loss disorder drug
29/12/2023 18:36
** Drug developer MyMD Pharmaceuticals' MYMD.O shares gain
as much as 13% to $0.28 in volatile trading
** Company says its lead experimental drug, to treat a type
of muscle loss disorder called sarcopenia, met both primary
mid-stage study goals
** Sarcopenia is a progressive and generalized skeletal
muscle condition that commonly affects the elderly population
and causes patients to have a decline in muscle mass, among
other symptoms
** The drug candidate, MYMD-1, reduced levels of two
biomarkers that are common in several chronic inflammatory
diseases - company
** MYMD-1 also met all secondary safety and tolerability
goals needed to advance the clinical program, company says
** Company adds full study results will be released in 2024
** Including session's gain, stock down ~75% YTD
(Reporting by Pratik Jain in Bengaluru)
((Pratik.Jain@thomsonreuters.com))